Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
OBJECTIVE
An important cytotoxic effect of 5-fluorouracil (5-FU) is the inactivation of thymidylate synthase (TS) (EC 2.1.1.45) activity by the formation of a ternary complex consisting of covalently bound 5-fluorodeoxyuridine 5'-monophosphate (FdUMP), TS and 5,10-methylenetetrahydrofolate (CH2FH4). The gastrointestinal (GI) toxicity of 5-FU is also caused by its phosphorylation in the GI tract. Potassium oxonate (O(XO)) competitively inhibits pyrimidine phosphoribosyltransferase (EC 2.4.2.10), which converts 5-FU to 5-fluorouridine 5'-monophosphate (FUMP) in vitro. In this study the benefits of combining Oxo and tegafur (FT), which is a masked compound of 5-FU, in reducing the GI toxicity of 5-FU and in protecting the activity of TS in the normal GI tissues were evaluated.


METHODS
We administered orally a preparation of 1 M FT and 0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP) with or without 1 M O(XO) (called S-1 and FT + CDHP, respectively) or vehicle only (control) to rats for ten consecutive days and compared the toxicity, the histopathological findings and the free TS activity in the GI tissues of the treated rats.


RESULTS
During the experimental periods, the signs of toxicity, such as a decrease in body weight, diarrhea and death, were only observed in the rats treated with FT + CDHP. The histopathological findings in the ileum and colon samples from rats treated consecutively with S-1 on day 1, day 4, day 7 and day 10 were less frequent and more mild than in the samples from rats treated with FT + CDHP. Furthermore, the free TS activities in the ileum samples of rats given S-1 and FT + CDHP were significantly decreased compared with the activity in samples from the control rats throughout the experimental periods. The free TS activities in GI tissues of rats treated with S-1 were higher than the TS activities in tissues from rats treated with FT + CDHP daily from day 4 to day 10, although activities in S-1-treated rat were decreased to almost same low levels as in FT + CDHP-treated rats on day 1.


CONCLUSIONS
Our results suggest that repeated simultaneous administration of Oxo and FT can effectively protect the activity of TS by decreasing FdUMP via FUMP from 5-FU in GI tissue, and may lead to a reduction in GI toxicity.
Pharmacokinetics Research Laboratory, Tokushima Research Center, Taiho Pharmaceutical Co. Ltd., Japan. kuni-yosisue@taiho.co.jp
K
K
Yoshisue
K
K
Hironaga
S
S
Yamaguchi
A
A
Yamamoto
S
S
Nagayama
Y
Y
Kawaguchi
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D003106:Colon / Q000187:drug effects; D003967:Diarrhea / Q000139:chemically induced; D004064:Digestive System / Q000187:drug effects*; D004338:Drug Combinations; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D005468:Fluorodeoxyuridylate / Q000378:metabolism; D005472:Fluorouracil / Q000009:adverse effects* / Q000494:pharmacology; D007082:Ileum / Q000187:drug effects; D008297:Male; D010094:Oxonic Acid / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D005641:Tegafur / Q000494:pharmacology*; D013940:Thymidylate Synthase / Q000378:metabolism*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D011725:Pyridines; D005468:Fluorodeoxyuridylate; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D013940:Thymidylate Synthase; D005472:Fluorouracil; C104201:gimeracil